Screening for ovarian cancer

Cancer Control

Volumn 18, Issue 1, 2011, Pages 16-21

  Cragun, Janiel Marie ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER SCREENING; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; ECHOGRAPHY; FUNCTIONAL PROTEOMICS; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; OVARY CANCER; PATIENT ASSESSMENT; PELVIC EXAMINATION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 78651507047     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800103     Document Type: Article

References (47)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA; American Cancer Society: 2010.
2. American Cancer Society. How is ovarian cancer staged? 2009. http://www.cancer.org/docroot/cri/content/cri_2_4_3x_how_is_ovarian_ cancer_staged_33.asp. Accessed September 1, 2010.
3. Clarke-Pearson DL. Clinical practice. screening for ovarian cancer. N Engl J Med. 2009;361(2):170-177.
4. Wilson JMG, Jungner G. Principles and Practic of Screening for Disease. Geneva: World Health Organization; 1968:14-39. http://whqlibdoc. who.int/php/WHO_PHP_34.pdf. Accessed September 1, 2010.
5. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10(4):327-340.
6. Bast RC Jr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15(suppl 3):274-281.
7. Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Markers. 2007;23(5-6):397-410.
8. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3(4):355-366.
9. Screening for Ovarian Cancer, Topic Page. May 2004. US Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/ uspstf/uspsovar.htm. Accessed September 1, 2010.
10. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109 (2):221-227.
11. The Gynecologic Cancer Foundation. The Gynecologic Cancer Foundation Announces First National Consensus On Ovarian Cancer Symptoms. Chicago, IL; 2007. http://www.wcn.org/downloads/GCF_Press_ Release_June2007.pdf. Accessed September 1, 2010.
12. Andersen MR, Goff BA, Lowe KA, et al. Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116(3):378-383.
13. Andersen MR, Goff BA, Lowe KA, et al. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer. 2008;113(3):484-489.
14. Myers ER, Bastain LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment. Number 130. Prepared by the Duke Evidence-based Practice Center, Durham, NC, under Contract No. 290-02-0025. AHRQ Publication No. 06-E004. Rockville, MD: Agency for Healthcare Research and Quality. US Dept of Health and Human Services; 2006. http://www.ahrq.gov/downloads/pub/evidence/pdf/adnexal/adnexal.pdf. Accessed September 1, 2010.
15. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 1998;44(7):1379-1380.
16. Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn. 2009;3(6):597-605.
17. Helzlsouer KJ, Bush TL, Alberg AJ, et al. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 1993;269(9):1123-1126.
18. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267-277.
19. Myers ER, Havrilesky LJ, Kulasingam SL, et al. Genomic Tests for Ovarian Cancer Detection and Management. Evidence Report/Technology Assessment. Number 145. Prepared by the Duke University Evidence-based Practice Center, Durham, NC, under Contract No. 290-02-0025.) AHRQ Publication No. 07-E001. Rockville, MD: Agency for Healthcare Research and Quality. US Dept of Health and Human Services; 2006. http://www.ahrq.gov/ downloads/pub/evidence/pdf/genomicovc/genovc.pdf. Accessed September 1, 2010.
20. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76(10 suppl):2004-2010.
21. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000;77(3):350-356.
22. van Nagell JR Jr, DePriest PD, Ueland FR, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007;109(9):1887-1896.
23. National Cancer Institue. Ovarian Cancer Screening (PDQ) Health Professional Version. http://www.cancer.gov/cancertopics/pdq/screening/ ovarian/healthprofessional/allpages. Accessed September 1, 2010.
24. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005;23(31):7919-7926.
25. Skates S, Pauler D, Jacobs I. Screening based on the risk of cancer calculation from bayesian hierarchical changepoint and mixture models of longitudinal markers. J Am Stat Assoc. 2001;96(454):429-439.
26. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003;21(10 suppl):206s-210s.
27. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193(5):1630-1639.
28. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359(9306):572-577.
29. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst. 2005;97(4):315-319.
30. Society of Gynecologic Oncologists. Society of Gynecologic Oncologists Statement Regarding OvaCheckTM. Chicago, IL; 2004.
31. Check E. Proteomics and cancer: running before we can walk? Nature. 2004;429(6991):496-497.
32. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14(4):1065-1072.
33. US Food and Drug Administration. OvaSureTM Manufacturer Letter. August 7, 2008. http://www.fda.gov/MedicalDevices/DeviceRegulationand-Guidance/IVDRegulatoryAssistance/ucm125130.htm. Accessed September 1, 2010.
34. Society of Gynecologic Oncologists. Society of Gynecologic Oncologists Statement Regarding OvaSureTM. July 2, 2008. http://ovariancancer. about.com/b/2008/08/10/ovasuretm-and-ovarian-cancer-screening.htm. Accessed September 1, 2010.
35. US Food and Drug Administration. FDA Clears a Test for Ovarian cancer. September 11, 2009. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2009/ucm182057.htm.Accessed September 1, 2010.
36. Daly MB, Ozols RF. The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics. Cancer Cell. 2002;1(2):111-112.
37. Schorge JO, Modesitt SC, Coleman RL, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010;119(1):7-17.
38. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998;178(4):670-677.
39. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81(2):214-218.
40. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
41. Woodward ER, Sleightholme HV, Considine AM, et al. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both highrisk and population risk women is ineffective. BJOG. 2007;114(12):1500-1509.
42. Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1365-1372.
43. Donach M, Yu Y, Artioli G, et al. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol. 2010;31(3):209-215.
44. van der Velde NM, Mourits MJ, Arts HJ, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer. 2009; 124(4):919-923.
45. Olivier RI, Lubsen-Brandsma MA, Verhoef S, et al. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol. 2006;100(1):20-26.
46. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010;8(5):562-594.
47. Fung MF, Bryson P, Johnston M, et al. Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can. 2004; 26(8):717-728.